Anton Gopka

Co-Founder, Investor at Longevica

Anton Gopka's work experience includes co-founding and managing ATEM Capital, a New York-based Life Sciences investment firm focused on breakthrough bioplatforms, medical devices, diagnostics, and digital health solutions. Anton has also served as an investor for various biotech companies, including Deka Biosciences, Amolyt Pharma, Arpeggio Biosciences, Triumvira Immunologics, Iridia Inc., and the National Cancer Institute. Anton is the CEO and Founder of GATE Leadership School, an online platform for tech entrepreneurs and professionals. Anton has also founded two other startups with a focus on technology.

Anton Gopka's education history includes various courses and certifications in different fields. In 2005, they passed the CFA Level I examination from the CFA Institute, focusing on Corporate Finance. In 2008, they pursued Corporate Finance studies at INSEAD. Later, in 2014, Anton attended Harvard Business School for a course on Board Leadership.

In 2015, Anton obtained several verified certificates. Anton completed a course at Osaka University called "BIO101x, The Immune System: New Developments in Research." Anton also studied "Fundamentals of Immunology" through a course at Rice University called "BIOC372.1x" and "Making Biologic Medicines for Patients" at the Massachusetts Institute of Technology. Additionally, Anton acquired a verified certificate in "Biology of Cancer" at The Johns Hopkins University in 2016.

Outside of Anton's formal education, they acquired several certifications. In 2015, they obtained a verified certificate from Rice University for "Fundamentals of Immunology." In the same year, they also completed a verified certificate for "Making Biologic Medicines for Patients" from the Massachusetts Institute of Technology. Anton's additional certifications also include a verified certificate for "Introduction to the Biology of Cancer" from The Johns Hopkins University in 2016 and a Music + Web 3.0 Bootcamp certification from Blockchain at Berkeley in 2023.

Links

Timeline

  • Co-Founder, Investor

    April, 2022 - present

View in org chart